Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) EPS (Weighted Average and Diluted) (2021 - 2026)

Unicycive Therapeutics filings provide 3 years of EPS (Weighted Average and Diluted) readings, the most recent being -$2.64 for Q4 2024.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 1550.0% to -$2.64 in Q4 2024 year-over-year; TTM through Dec 2024 was -$5.21, a 535.37% decrease, with the full-year FY2025 number at -$1.67, up 70.44% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$2.64 in Q4 2024 for Unicycive Therapeutics, down from -$0.46 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.13 in Q3 2023 to a low of -$2.64 in Q4 2024.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$0.36 (2022), compared with a mean of -$0.66.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 64.76% in 2023 and later tumbled 1550.0% in 2024.
  • Unicycive Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.35 in 2022, then skyrocketed by 54.78% to -$0.16 in 2023, then tumbled by 1550.0% to -$2.64 in 2024.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$2.64 (Q4 2024), -$0.46 (Q3 2024), and -$1.5 (Q2 2024) per Business Quant data.